A Bayer partner that co-developed an FDA-approved prostate cancer drug is joining some of its biotech compatriots and taking out its restructuring kit, announcing a swath of R&D changes and warning of potential layoffs Thursday morning. The Finnish biotech Orion revealed wholesale changes to its pipeline focus, saying it will halt its research into neurodegenerative … Continue reading A Bayer partner slims down, trimming R&D and enacting layoffs, to better focus on the pair’s prostate cancer work